INTRODUCTION
Human immunodeficiency virus (HIV) infection results in a functional impairment of CD4 T cells long before a quantitative decline of this lymphocyte subset becomes evident. This defect has been documented in a high percentage of HIV-infected individuals whose CD4 lymphocytes fail to proliferate in response to antigenic stimulation and may have relevant consequences on the capacity of the immune system to mount an effective response to HIV or to other pathogens [1] [2] [3] [4] [5] . The inability of HIV-exposed T cells to generate a vigorous response to antigens has been associated with an alteration in interleukin (IL)-2 production and an enhanced susceptibility to apoptosis of the lymphocytes [6 -8] . Several reports have investigated the molecular bases of T cell abnormalities in HIV infection providing evidences for multiple defects in the early T cell receptor (TCR)-mediated signaling pathways. CD4 and CD8 T lymphocytes from AIDS patients showed a significant decrease in CD3-expression, which appeared to be reversible upon reduction of the virus load with highly active antiretroviral treatment [9] . A marked decrease in the enzymatic activity of CD45 and altered levels of Lck and Fyn have been observed in lymphocytes isolated from HIV-infected individuals [10 -16] . Most of these defects can be reproduced in vitro by exposure of normal T lymphocytes to inactivated HIV virions or purified HIV components. In fact, soluble (s)gp120 is able to inhibit IL-2 mRNA expression [17] and the proliferative response of T lymphocytes when stimulated through the TCR [18, 19] . The ability of envelope glycoprotein gp120 (HIVenv) to interfere with TCR-mediated activation of the src-family tyrosine kinases also has been documented [20 -22] . We proposed that the effects of gp120 on antigen-dependent proliferation of T lymphocytes are not homogenous and may vary according to their state of activation and differentiation [23] . Naive and memory CD4 subsets show differential susceptibility, although the exposure of CD4 naive T cells to the envelope glycoprotein results in a marked inhibition of the mitogenic responses, the growth of the memory subset is less severely restrained by gp120 [23] . This inhibitory effect is associated with alterations in the TCR-mediated signaling such as inhibition of the extracellular-regulated kinase (ERK) and stimulation of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA).
PKA is a serine/threonine kinase that regulates a number of cellular processes important for immune activation [24] . In lymphocytes, PKA regulates antigen receptor-induced signaling by altering protein-protein interactions and by changing the enzymatic activity of target protein [25] . Stimulation of the cAMP/PKA pathway may also increase the level of inducible cAMP early repressor and cAMP-responsive element modulator, two nuclear inhibitory factors involved in modulation of T cell responsiveness by their capacity to transcriptionally attenuate IL-2 gene expression [26, 27] . Hofmann et al. [28] suggested the involvement of PKA in the mechanism leading to the HIV-induced defect in T cell function. More recently, this hypothesis has been corroborated by direct measurements of the cAMP intracellular levels in T lymphocytes derived from HIVϩ individuals and by the ability of PKA type I antagonist to restore the responsiveness of T cells from HIV-infected patients [29, 30] . Although these reports revealed an involvement of the PKA pathway in the mechanism leading to T cell abnormalities in HIV infection, the molecular base of this phenomenon is still unclear. Here, we provide novel evidences on the ability of the soluble envelope glycoprotein to induce long-lasting effects on naive lymphocytes through a CD4-independent, PKA-mediated pathway. This phenomenon may contribute to the development of immune defects in HIV-1 infected individuals.
MATERIALS AND METHODS

Cell culture and reagents
Complete medium was RPMI-1640 medium supplemented with 2 mM Lglutamine, 1% sodium piruvate, 1% nonessential amino acids (all from Life Technologies, Rockville, MD), and 10% heat-inactivated fetal calf serum (FCS; Hyclone laboratories, Logan, UT). H89 (Sigma Chemical Co., Milan, Italy) and PP1 (Alexis, Lausen, Switzerland) were dissolved in dimethyl sulfoxide and added at the final concentration of 10 M. The anti-CD4 antibody Leu3a was from Becton Dickinson (San Jose, CA). Human stromal cell-derived factor-1 (hSDF-1)␣ was from Alexis. sh-recombinant CD4 (shrCD4), rgp120 IIIB (HIVenv), and biotinylated rgp120 were from Intracell Corp. (London, UK). sCD4-HIVenv complexes were generated by incubating sCD4 and HIVenv in serum-free medium at a 1:1 ratio for 1 h at 4°C before being added to cells at the final concentration of 2 g/ml.
Purification of naive CD4 T lymphocytes
T lymphocytes were isolated from peripheral blood of healthy donors by Lymphoprep (Nyegaard and Co., Oslo, Norway) density-gradient centrifugation at 2500 rpm for 30 min and subsequently, by incubating mononuclear cells for 1 h at 37°C in plastic petri dishes. Resting T cells were then purified from nonadherent cells by nylon wool (Robbins Scientific, Sunnyvale, CA) adherence to remove B cells, followed by a two-step (40% and 50%, respectively) Percoll gradient (Pharmacia Biotech, Uppsala, Sweden). Resting lymphocytes were recovered from the high-density cell fraction. The CD4ϩ and CD8ϩ CD45RA cells were separated using negative selection with subset-specific monoclonal antibodies (mAb; anti-CD8, -CD19, -DR, -CD45RO, CD16, -CD56, -␥␦ TCR, all from Becton Dickinson) and anti-mouse immunoglobulincoated magnetic beads (Dynabeads, Dynal, Oslo, Norwey). The purity of lymphoid populations was tested by flow cytometry (FACScan, Becton Dickinson) using appropriate mAb (PharMingen, San Diego, CA). Purified, naive lymphocytes contained 89 -93% of CD3ϩ CD45 RAϩ. Contaminating cells were CD8ϩ (4 -7%), CD45 ROϩ (3-5%), and CD3-CD56ϩ (3-10%). The purity of naive lymphocytes was also tested by functional assay: Stimulation with an optimal dose of phytohemagglutinin (PHA; 2 g/ml) did not induce a detectable mitogenic response. Conversely, an optimal response was observed upon addition to cultures of 10% of dendritic cells (DC) or anti-CD28 antibody (Becton Dickinson; data not shown).
Generation of monocyte-derived DC (Mo-DC)
Mo-DC were obtained according to protocol by Sallusto et al. [31] . Briefly, monocytes were isolated from peripheral blood mononuclear cells by adherence on plastic dishes coated with 2% gelatin. Adherent cells were removed by incubation with phosphate-buffered saline-EDTA and were cultured for 5 days at a density of 3 ϫ 10 6 cells/ml in RPMI 1640 containing 10% FCS supplemented with 50 ng/ml granulocyte macrophage-colony stimulating factor and 1000 U/ml IL-4 (Sigma Chemical Co.). The purity of isolated populations was tested by flow cytometry using the appropriate mAb.
Anergy assay
To test the capability of HIVenv to induce a prolonged hyporesponsivity state, namely anergy, naive lymphocytes were incubated with viral glycoprotein, rested in fresh medium, and stimulated with mitogens or allogenic Mo-DC. During the incubation step, 3-5 ϫ 10 6 purified T cells were cultured in the presence or absence of 1-2 g/ml rgp120 for 12-18 h. At the end of this incubation, lymphocytes were tested for viability, washed extensively, and rested in fresh medium for further 3-8 days (resting step). At the end of the resting step, Lymphoprep (Nyegaard and Co.) density gradient removed death cells, and living cells were tested for responsiveness to mitogens or allogenic Mo-DC (stimulation step). As tested in additional experiments, the purification step with Lymphoprep did not interfere with responsiveness and survival of lymphocytes. Proliferation assays were performed by culturing 10 5 lymphocytes/wells for 72 h in round-bottom 96 wells/plate with increasing doses of PHA (Sigma Chemical Co.) plus accessory cells (5% of plastic-adherent, allogenic cells). Mitogenic response to Mo-DC was tested by stimulation of T cells with increasing amounts of allogenic Mo-DC.
3 H-Thymidine (Amersham International, Buckinghamshire, UK) was added to cultures during the last 12 h of incubation.
Immunoblotting and immunocomplex kinase assays
Purified CD4 CD45 RA cells (5ϫ10 6 ) were preincubated for 30 min on ice in the presence or absence of rgp120 (2 g/ml) and then incubated at 37°C for different periods of time. Lymphocytes were lysed in 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40, 100 g/ml phenylmethylsulfonyl fluoride, 100 g/ml tosylphenylalanine chloromethyl ketone, 1 g/ml leupeptin, 0.83 g/ml chymostatin, 10 g/ml soybean trypsin inhibitor, 1 mM sodium orthovanadate, and 0.5 mM dithiothreitol. The lysates were boiled for 5 min and separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis was performed using mAb to Lck, phospho-ERK, ERK-2, cAMP response element-binding protein (CREB), and phospho-CREB (Santa Cruz Biotechnology, Santa Cruz, CA) and was developed using the enhanced chemiluminescence Western blotting kit (Amersham International).
PKA assays were performed in a final volume of 25 l at 30°C for 10 min. The kinase reaction mixture contained 100 M adenosine 5Ј-triphosphate (ATP), [␥ 32 P] ATP 10 Ci/100 ml, 10 mM MgCl 2 , 20 mM Hepes (pH 7.4), and 100 M Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide; Sigma Chemical Co.). Specificity of reaction was verified by adding 100 M protein kinase inhibitor (PKI; P0300) synthetic rabbit PKA-specific inhibitor pseudo-substrate (Sigma Chemical Co.) to a duplicate of each experimental point. Kemptide phosphorylation was monitored by spotting 20 l reaction mixture on phosphocellulode filters (Whatman, P81). After washing with phosphoric acid, 75 mM, radioactivity was determined by counting the filters in 4 ml scintillation liquid (Ecolite, ICN, Costa Mesa, CA). Free catalitic-PKA (C-PKA) activity was determined as PKI-inhibitable filter-bound radioactivity. Control assay indicated that 100 M PKI used did not inhibit the binding of phosphorylated Kemptide to phosphocellulose filters. Data were expressed as picomoles of [␥ 32 P] phosphate transferred to the peptide substrate during 10 min incubation.
Statistical analysis
Data were analyzed by Wilcoxon test for paired comparison by using the StatView SEϩ Graphic program for Macintosh (Abacus Concepts, Cary, NC).
RESULTS
HIVenv induces anergy in naive CD4
ϩ T cells
To evaluate the ability of the soluble envelope glycoprotein to induce long-lasting, biological effects in naive T lymphocytes, purified CD4 CD45RA lymphocytes were exposed to rHIVenv for a prolonged time (12-18 h) . At the end of this incubation, T cells were tested for viability, washed extensively, and rested in fresh medium for an additional 3-8 days (resting step). Finally, viable cells were isolated by density gradient, and their responsiveness to polyclonal mitogens and allogenic DC was tested. The exposure of naive T cells to HIVenv did not induce a significant increase in T cell death at any step of the experimental procedure (Fig. 1) . However, lymphocytes cultured with the viral glycoprotein showed a marked decrease in the mitogenic response to PHA and allogenic DC stimulation (Fig. 1 ). This effect was dependent on an increase in the activation threshold as revealed by statistical analysis, showing that the exposure to rgp120 reduced significantly (PϽ0.001) the response of naive T cells to suboptimal stimuli (PHA or allogenic DC) but was less effective at higher doses of mitogens.
Anergy-induced gp120 may be dependent on the prolonged down-regulation of CD4 from cell surface, a receptor able to stabilize major histocompatibility complex:peptide/TCR complexes and to transduce activating signals in T cells. To verify this hypothesis, we compared kinetics of HIVenv-induced CD4 down-regulation with the persistence of hyporesponsiveness. In parallel, cell-surface expression of CXCR4 and CD3-ε was also evaluated. After 12 h of incubation with HIVenv, 80% of CD4 and 40% CXCR4 molecules were removed from the cell surface, and no change in CD3-ε expression was observed (Fig.  2) . During the resting step, CD4 and CXCR4 surface levels progressively recovered until at later time points, no difference was found between HIVenv-treated and untreated lymphocytes (Fig. 2) . These data indicate that the effects induced by HIVenv on CD4 expression were transient and required the continuous presence of the HIVenv in the culture medium. Conversely, a Fig. 1 . Effects induced by transient exposure of naive T cells to purified HIVenv. Purified CD4ϩ CD45 RA lymphocytes were exposed for 12 h to 2 g/ml rgp120, washed, and rested for 72 h in fresh medium. At different times, aliquots of T cells were stained with Annexin V and analyzed by flow cytometry. The left panel reports the percentage of Annexin V-positive cells upon 12 h of exposure to rgp120 at the end of the resting step and 72 h from addition of PHA 2 g/ml (stimulation step). Responsiveness of T cells to PHA or allogenic DC is shown in the middle and right panels, respectively. The results of the proliferation assays are expressed as the percent of the maximal response, assuming 100% the response of HIVenv-untreated lymphocytes to an optimal dose of PHA (2 g/ml; 75,000Ϯ12,000 cpm of 3 H-thymidine incorporation) or to 50,000 allogenic DC/well (35,000Ϯ5400 cpm). Each data point represents the mean of three independent experiments Ϯ SD. *, Statistical significant differences (PϽ0.001) were observed between the proliferation values measured in HIVenv-treated and untreated samples stimulated with 1 g/ml PHA or 5000 allogenic DC/well, respectively (center and right panels).
Fig. 2. Kinetic analysis of the effects induced by
HIVenv on naive T cells. CD4ϩ naive lymphocytes were exposed to HIVenv for 12 h, washed, and rested in fresh medium. The expression of CD4, CXCR4, and CD3-ε has been tested by flow cytometry at different time points. The results have been reported as the percentage of the maximum corresponding to the cellsurface expression levels measured in untreated lymphocytes. Inset reports the results of the anergy assay. Briefly, upon exposure to HIVenv, T cells were washed and rested for 72 h in fresh medium before being stimulated with T cell responsiveness to PHA (1 g/ml) or allogenic DC (5000 cell/well). The results have been reported as the percentage of the maximum proliferation measured in HIVenv-unexposed lymphocytes stimulated with the optimal doses of PHA or allogenic DC. ( 3 H-Thymidine incorporation was 41,000Ϯ7000 and 25,000Ϯ3500 cpm, respectively.) Each data point reports the mean of three independent experiments Ϯ SD. pulsed exposure to HIVenv was able and sufficient to induce a prolonged hyporesponsiveness in naive T lymphocytes to PHA and allogenic DC stimulation (Fig. 2, inset) .
Analysis of early biochemical changes induced by HIVenv in CD4ϩ naive T cells
To identify the biochemical pathway responsible for the induction of anergy, we analyzed the activation status of several tyrosine kinases in HIVenv-exposed and unexposed, naive lymphocytes. As the viral glycoprotein binds to CD4, we should expect that the incubation with HIVenv should stimulate Lck activity. Of note, we found no difference in Lck autophosphorylation activity between HIVenv-treated and untreated lymphocytes (Fig. 3) . These data were confirmed by Western blot analysis showing no shift-up of the Lck band (Fig. 3) . To further analyze the proximal signal pathway triggered by HIVenv, we measured the level of the phosphorylated form of ERK. These experiments showed that HIVenv was unable to stimulate the mitogen-activated protein kinase (MAPK) pathway in naive T lymphocytes (Fig. 3) . Finally, we measured the effects induced by HIVenv treatment on PKA and on the phosphorylation status of CREB, a putative PKA substrate. PKA phosphotransferase activity was analyzed in naive T cells exposed to HIVenv for short periods of time (5-30 min) by an in vitro kinase assay on a synthetic peptide. Western blotting revealed the phosphorylated and unphosphorylated forms of CREB by using appropiate commercial antibodies (see Materials and Methods for details). As shown in Figure 3 , HIVenv stimulated the PKA activity and induced a progressive phospho-CREB accumulation.
Role of CD4 in HIVenv-induced anergy
CD4 plays a key role in the pathogenesis of HIV infection by its ability to bind the envelope glycoprotein and to transduce inhibitory signals responsible for apoptosis or anergy [32] [33] [34] [35] . In this set of experiments, we analyzed the effects of Leu3a, an anti-CD4 antibody, and SDF-1, the natural ligand of CXCR4 on anergy, and binding of HIVenv to the cell surface. The presence of Leu3a but not SDF-1 during the incubation step with rgp120 was effective in preventing the long-lasting, inhibitory effects exerted by the viral glycoprotein (Fig. 4) . In addition, treatment with Leu3a but not SDF-1 was effective in decreasing the binding of biotinylated HIVenv to the T cell surface (Fig. 4) . These findings indicate that CD4 but not CXCR4 is crucial to recruit HIVenv to the cell surface but not provide direct information regarding the ability of these receptors to transduce inhibitory signals. To investigate this point, we analyzed the effect induced by the prolonged exposure of naive CD4 T cells to Leu3a and SDF-1. As expected, exposure to Leu3a resulted in a marked down-regulation of CD4 from the cell surface; however, this phenomenon was not associated with the induction of anergy. Of note, Leu3a did not stimulate the PKA activity (Fig. 5) . The prolonged exposure of naive lymphocytes to SDF-1 resulted in a long-lasting hyporesponsiveness to antigen stimulation. This phenomenon was associated with marked down-regulation of CXCR4 from cell surface and with a detectable stimulation of the PKA activity (Fig. 5) . These findings indicated that although CD4 was responsible for binding of HIVenv to the cell surface, its ligation did not activate the inhibitory cascade in naive T lymphocytes.
The binding of sCD4 to HIVenv induces conformational changes in the virus glycoprotein: sCD4/HIVenv complex will be expected to bind CXCR4 but not the membrane CD4 receptor [36] . Therefore, this complex is a useful tool to investigate further the role of CD4 and CXCR4 molecules in the induction of anergy. In fact, we found that the preincubation of HIVenv with sCD4 prevents the ability of gp120 to downregulate the expression of CD4 from the cell surface without affecting its capability to induce a decrease in the level of CXCR4 expression (Fig. 5) . Of note, the pretreatment of HIVenv with sCD4 did not prevent the anergizing activity of the envelope glycoprotein and did not abrogate the ability of gp120 to trigger the PKA activity (Fig. 5) . Taken together, these findings confirmed the inability of CD4 to stimulate the PKA pathway and to transduce negative signals in naive T cells.
The pharmacological block of PKA prevented the HIVenv-induced anergy
HIVenv and sCD4-HIVenv complexes share a comparable ability to induce anergy in naive T cells, a phenomenon associated with their capability to stimulate the PKA pathway. This association strongly suggested an involvement of PKA in the mechanism of anergy. Therefore, we pretreated lymphocytes with H89 and PP1, selective inhibitors of PKA and tyrosine kinases, before being exposed to this moiety. This set of experiments showed that the pharmacological block of PKA but not of the tyrosine kinase activity prevented the hyporesponsiveness induced by lymphocyte exposure to the viral glycoprotein. These data provided direct evidence about the involvement of the PKA pathway in the mechanism of anergy induction (Fig. 6) .
DISCUSSION
Signal cascades mediated by the HIV-1 envelope glycoprotein gp120 have been proposed to influence HIV-1 replication as well as viral-associated cytopathicity and apoptosis [37] . The data presented here demonstrate the ability of HIVenv to induce a long-lasting, hyporesponsive state in CD4ϩ naive T cells through a mechanism that does not require a signaling mediated by the CD4 receptors. The analysis of the proximal signaling reveals that this phenomenon is associated with stimulation of the PKA/CREB pathway and is prevented by H89, a pharmacological inhibitor of PKA.
The ability of gp120 to modulate the biological response of lymphoid cells via a CD4-independent mechanism has been proposed by several authors. Fantuzzi and colleagues [38] have recently shown that the treatment of freshly isolated monocytes with rgp120-IIIB resulted in a dose-dependent enhancement of secretion of monocyte chemoattractant protein-1, macrophage inflammatory protein-1␤, and regulated on activation, normal T expressed and secreted. This phenomenon is independent by interaction of gp120 with CD4 but relates to the specific interaction of the viral glycoprotein with CCR5 and CXCR4 coreceptors. Other authors have found that in contrast to the CD4-dependent gp120 signaling via CCR5, the envelope-mediated CXCR4 signaling is CD4-independent and can induce chemotaxis of CD4 and CD8 T cells [39] . In our experimental model, treatment with Leu3a, a gp120 mimicking anti-CD4 antibody, induces a marked CD4 down-regulation but was unable to stimulate the PKA pathway as well as to induce anergy in naive T cells. Conversely, sCD4-HIVenv complexes, which are able to bind CXCR4 but not CD4, stimulate the PKA pathway and induce anergy in naive lymphocytes. These findings strongly support the hypothesis that CD4 molecules are required for the recruitment of the envelope glycoprotein to the T cell surface but are unable to mediate the negative signaling responsible for the induction of the prolonged hyporesponsiveness to mitogens. These data are in contrast with a number of reports showing that the engagement of CD4 by gp120 may induce pleiotropic effects and interfere with the activation process of T cells [13-16, 20 -22] . Other studies have also documented that gp120 can itself transduce intracellular signals via CD4 and CXCR4/CCR5 receptors, including the activation of the MAPK pathway [40, 41] . The majority of these studies have been performed on transformed T cell lines or on preactivated T lymphocytes. When signaling has been investigated on normal, quiescent T cells, it has been observed that Fig. 4 . Effects of anti-CD4 antibody and SDF-1 on HIVenv-induced anergy. Naive CD4ϩ lymphocytes were exposed to HIVenv (2 g/ml) in the presence or absence of Leu3a (0.5 g/ml) or SDF-1 (100 nM). (Left) Results of the anergy assay (see Materials and Methods). T cell responsiveness to allogenic (Allo) DC has been expressed as the percentage of the maximum proliferation measured in HIV-untreated T lymphocytes exposed to 50,000 allogenic DC/well corresponding to 35,000 Ϯ 8000 cpm 3 H-thymidine incorporation. Each data point reports the mean of three independent experiments Ϯ SD. (Right) Ability of Leu3a and SDF-1 to prevent the binding of HIVenv to the cell surface. In this set of experiments, naive CD4ϩ lymphocytes were exposed for 2 h to biotinylated HIVenv (250 ng/ml) in the presence or absence of Leu3a (0.5 g/ml) or SDF-1 (100 nM). Phycoerythrin (PE)-conjugated avidin was used to detect the binding of biotinylated HIVenv. The filled, gray profile refers to PE-avidin staining, measured on T cells preincubated with biotinylated HIVenv (maximal staining). Open, thick profiles refer to PE-avidin staining measured in cells preincubated with biotinylated HIVenv in the presence of Leu3a or SDF-1. Open, dotted profile refers to PE-avidin staining measured in lymphocytes not exposed to biotinylated HIVenv (negative control). The result is representative of three independent experiments. gp120 may induce differential effects on and activate different signal cascades in resting and preactivated lymphocytes [23, 41] . One apparent distinction between primary, quiescent T lymphocytes compared with preactivated lymphocytes or the transformed Jurkat cell line is that in the former, a significant proportion of CD4 is outside the lipid rafts [42, 43] , whereas in the latter, it is located almost exclusively in raft structures [44, 45] . This localization may be one of the factors accounting for the HIVenv signaling responses observed in the naive T lymphocytes and may explain the differential effects exerted by the envelope glycoprotein on the different T cell subsets.
The ability of HIV to stimulate PKA activity was originally shown a decade ago by Hofmann et al. [28] by exposing normal peripheral blood lymphocytes to inactivated virions. Here, we clarify the molecular bases of this phenomenon by identifying HIVenv as a viral derivative responsible for PKA activation in naive T cells, showing for the first time that this biochemical change is not dependent on CD4-mediated signals. The coupling of the chemokine receptor CXCR4 to the PKA pathway has been documented recently in embryonic retinal ganglion cell neurons and in peripheral blood monocyte [46, 47] . Here, we confirm these findings, revealing for the first time the ability of SDF-1␣ to trigger the PKA pathway and to induce prolonged effects on the activation threshold in CD4ϩ naive T cells. Activation of the PKA pathway has a variety of transcriptional and post-transcriptional effects on different immune mediators. It has been reported that increased levels of cAMP have an important post-transcriptional effect on CD40 ligand expression, IL-10 secretion, and T helper cell type 2 (Th2) activation, and it inhibits T cell proliferation, IL-2 and IL-12 production, and Th1-mediated effector functions [48 -53] . In addition, it has been shown that TCR stimulation of naive CD4 T cells in the presence of cAMP-elevating agents leads to a population of CD4 CD45RA T cells with functional and phenotypic features of effector Th2 cells [54] . Here, we found that HIVenv glycoprotein can induce anergy in naive T cells by stimulating the PKA pathway, a phenomenon whose relevance remains to be determined in the context of the mechanisms affecting homeostatic proliferation, clonal expansion, and terminal differentiation of this subset of lymphocytes in AIDS. Despite this, our findings offer an ensemble of the complex and differential effects that HIV derivatives can exert on the various hematopoietic cell types. Naive T lymphocytes were exposed for 12 h to rgp120 (2 g/ml) in the presence or absence of PKA and tyrosine kinase inhibitors (H89 10 M and PP1 10 M, respectively). Lymphocytes were washed, rested for 96 h, and exposed for 72 h to an increasing number of allogenic DC.
3 H-Thymidine was added in the last 12 h of culture. The results are expressed as the percentage of the maximal response measured in HIVenv-untreated lymphocytes stimulated with 50,000 allogenic DC (47,000ϩ4000 cpm) and are calculated on three independent experiments. Statistical significant differences (PϽ0.001) were observed between the proliferation values measured in HIVenv-treated lymphocytes cultured with or without PP1 and untreated lymphocytes stimulated with 5000 allogenic DC/well cultured in regular medium or in the presence of HIVenv and H89. 5 . CD4 engagement by HIVenv or Leu3a is not required for the induction of T cell anergy in naive lymphocytes, which were cultured for 12 h with regular medium, Leu3a (0.5 g/ml), SDF-1 (100 nM), HIVenv (2 g/ml), or sCD4-gp120 complexes (sCD4-HIVenv; 2 g/ml). To evaluate T cell responsiveness, lymphocytes were rested for 3 days in fresh medium before being stimulated with 10,000 cells/well allogenic DC (top). The results are expressed as the percentage of the maximal response measured in lymphocytes cultured in regular medium (38,000Ϯ2500 cpm). Aliquots of cells exposed for 12 h to the stimuli described previously were double-stained with CD4 and CXCR4 and analyzed by flow cytometry (middle). The results are expressed as the percentage of the maximum mean fluorescence intensity measured on lymphocytes cultured with regular medium alone. (Bottom) Phosphotransferase activity of the C-PKA measured in naive T cells exposed for 30 min to the reported stimuli (Leu3a, 0.5 g/ml; SDF-1, 100 nM; HIVenv, 2 g/ml; sCD4-HIVenv, 2 g/ml). The results are representative of four independent experiments.
